Drug Details
| General Information of the Drug (ID: DR0904) | ||||
|---|---|---|---|---|
| Name |
Bicalutamide
|
|||
| Synonyms |
Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Prostate cancer [ICD-11: 2C82] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Absorption
The drug is well-absorbed following oral administration
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability
Clearance
The apparent oral clearance of drug is 0.32 L/h
Half-life
The concentration or amount of drug in body reduced by one-half in 5.9 days
Metabolism
The drug is metabolized via the glucuronidation
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.93549 micromolar/kg/day
Water Solubility
The ability of drug to dissolve in water is measured as 0.005 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C18H14F4N2O4S
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
|
|||
| InChI |
1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
|
|||
| InChIKey |
LKJPYSCBVHEWIU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 90357-06-5
|
|||
| ChEBI ID | ||||
| GDSC | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MUC1 | Molecule Info | |||
| Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
| DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
| LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
There are synergistic effects of curcumin and bicalutamide. Curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein. | |||||
| Epigallocatechin gallate | Hamamelis virginiana | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SOD Mn | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Up-regulation | Apoptosis | ||||
| In-vitro Model | NRP-152 | CVCL_4869 | Healthy | Rattus norvegicus | ||
| NRP-154 | CVCL_4870 | Healthy | Rattus norvegicus | |||
| Experimental
Result(s) |
Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Androgen receptor (AR) | Molecule Info | [4] | |
| KEGG Pathway | Oocyte meiosis | Click to Show/Hide | ||
| 2 | Pathways in cancer | |||
| 3 | Prostate cancer | |||
| NetPath Pathway | EGFR1 Signaling Pathway | Click to Show/Hide | ||
| 2 | AndrogenReceptor Signaling Pathway | |||
| 3 | FSH Signaling Pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Coregulation of Androgen receptor activity | |||
| 3 | Regulation of Androgen receptor activity | |||
| 4 | Nongenotropic Androgen signaling | |||
| 5 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| 6 | FOXA1 transcription factor network | |||
| 7 | Notch-mediated HES/HEY network | |||
| Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
| 2 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | |||
| WikiPathways | SIDS Susceptibility Pathways | Click to Show/Hide | ||
| 2 | Integrated Pancreatic Cancer Pathway | |||
| 3 | Prostate Cancer | |||
| 4 | Integrated Breast Cancer Pathway | |||
| 5 | Nuclear Receptors | |||
| 6 | Androgen receptor signaling pathway | |||
